[Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma].
We measured rituximab concentrations in the cerebrospinal fluid (CSF) in 2 patients with diffuse large B-cell lymphoma in whom central nervous system (CNS) invasion had developed. They received rituximab intravenously following irradiation therapy (patient no.1) or along with chemotherapy (patient no.2). The rituximab concentrations in the CSF were considered to be very low (0.2-0.6 microg/ml), and could not be increased significantly by serial intravenous administrations of rituximab. The lymphoma relapsed in patient no.1, and the combined therapy was not effective in patient no.2. An alternative approach such as intrathecal administration of rituximab could be anticipated as a new therapeutic strategy for CNS lymphoma.
Kikuchi
Ako
A
Division of Hematology/Oncology, Department of Medicine, Tokai University School of Medicine.
Kawada
Hiroshi
H
Iwaki
Yasunobu
Y
Machida
Shinichirou
S
Tsuchiya
Takahide
T
Fukuda
Ryuki
R
Hotta
Tomomitsu
T
D000368:Aged; D000911:Antibodies, Monoclonal / Q000134:cerebrospinal fluid*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000134:cerebrospinal fluid*; D001932:Brain Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab